Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(obinutuzumab)
461 results
  • Risk of infection associated with new therapies for the treatment of lymphoproliferative syndromes. [Review]
    Med Clin (Barc) 2019Los-Arcos I, Aguilar-Company J, Ruiz-Camps I
  • Over the last decade, there have been important developments in the treatment of lymphoproliferative disorders. Apart from conventional chemotherapy, a wide array of therapies has been developed, with different indications. The aim of this review is to evaluate the risk of infection associated with these therapies, as well as establishing prevention recommendations. In all cases, the patient's un…
  • BCL-2 Inhibitors, Present and Future. [Journal Article]
    Cancer J 2019 Nov/Dec; 25(6):401-409Ryan CE, Davids MS
  • The members of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins are key regulators of the intrinsic apoptotic pathway; dysregulation of this pathway leads to pathologic survival of cancer cells. B-cell leukemia/lymphoma-2 had long been viewed as a promising target for the treatment of several hematologic malignancies, specifically chronic lymphocytic leukemia (CLL), yet for many years th…
  • Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. [Journal Article]
    Expert Rev Hematol 2019Khan Y, Lyou Y, … O'Brien S
  • Introduction: The treatment paradigm of chronic lymphocytic leukemia (CLL) has changed significantly in the last few years. There are multiple frontline therapy options for the treatment of CLL, including chemoimmunotherapy, ibrutinib and most recently venetoclax with obinutuzumab. The role of chemoimmunotherapy has declined significantly for patients with CLL and novel agents are now being used …
  • Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. [Journal Article]
    Blood 2019; 134(21):1796-1801Woyach JA
  • The management of chronic lymphocytic leukemia (CLL) has undergone dramatic changes over the previous 2 decades with the introduction of multiple new therapies and new combinations. Management of the newly diagnosed asymptomatic patient has not significantly changed outside of the development of a number of prognostic factors and the CLL International Prognostic Index, which is helpful in discuss…
  • Complete resolution of chylopericardium after chemotherapy for chronic lymphocytic leukemia. [Case Reports]
    Curr Oncol 2019; 26(5):e696-e699Morris AL, Colbourne T, … Banerji V
  • Nontraumatic chylous pleural effusions (chylothorax) and pericardial effusions (chylopericardium) are rare. They can, however, accompany intrathoracic malignancies and, most commonly, lymphomas. An association of chronic lymphocytic leukemia (cll) with chylopericardium has rarely been reported. A 68-year-old woman with cll, previously treated with single-agent fludarabine in the community, develo…
New Search Next